Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 84.15% is 127% above its 5-year average of 37.04%, near the high end of its 5-year range (-33.65%–85.61%).
59.14% above its 12-month average of 52.88%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 36.60%.
GROSS MARGIN
84.15%
GROSS MARGIN AVG TTM
52.88%
GROSS MARGIN AVG 3Y
43.65%
GROSS MARGIN AVG 5Y
37.04%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+59.14%
CURRENT VS 3Y AVG
+92.80%
CURRENT VS 5Y AVG
+127.19%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.32%
median of 765 covered companies
CURRENT VS SECTOR MEDIAN
+108.71%
vs the sector median at left
Pulsenmore Ltd. Ordinary Shares
Market Cap
$14.57M
Gross Margin
84.15%
TTM Avg
52.88%
3Y Avg
43.65%
5Y Avg
37.04%
Market Cap
$14.97M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-2.45%
Market Cap
$13.83M
Gross Margin
-19.74%
TTM Avg
7.58%
3Y Avg
35.31%
5Y Avg
31.20%
Market Cap
$13.78M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$13.72M
Gross Margin
64.68%
TTM Avg
63.93%
3Y Avg
63.08%
5Y Avg
61.52%
Market Cap
$15.42M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-33.27%
Market Cap
$13.48M
Gross Margin
-486.44%
TTM Avg
-208.47%
3Y Avg
-109.22%
5Y Avg
-72.81%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pulsenmore Ltd. Ordinary Shares (PLSM) | $14.57M | 84.15% | 52.88% | 43.65% | 37.04% |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.97M | 0.00% | 0.00% | 0.00% | -2.45% |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.09M | N/A | N/A | N/A | N/A |
| Sintx Technologies, Inc. (SINT)vs › | $13.83M | -19.74% | 7.58% | 35.31% | 31.20% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.78M | 0.00% | 0.00% | 0.00% | 0.00% |
| Vyome Holdings, Inc. (HIND)vs › | $13.72M | 64.68% | 63.93% | 63.08% | 61.52% |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.42M | 0.00% | 0.00% | 0.00% | -33.27% |
| IN8bio, Inc. (INAB)vs › | $13.52M | 0.00% | 0.00% | 0.00% | 0.00% |
| Optimi Health Corp. (OPTH)vs › | $13.48M | -486.44% | -208.47% | -109.22% | -72.81% |
| BioCardia, Inc. (BCDA)vs › | $15.78M | 0.00% | -3731.89% | -2384.22% | -1567.12% |
Gross Margin
84.2%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 36.60% |
| 2025-12-31 | 85.61% |
| 2025-06-30 | 36.43% |
| 2024-12-31 | 38.05% |
| 2024-06-30 | 35.77% |
| 2023-12-31 | 32.04% |
| 2023-06-30 | 41.03% |
| 2022-12-31 | 50.73% |
| 2022-06-30 | 39.96% |
| 2021-12-31 | 44.87% |
| 2021-06-30 | -33.65% |
